Artemisinin and its derivatives (ART) are crucial first-line antimalarial drugs that rapidly clear parasitemia, but recrudescences of the infection frequently follow ART monotherapy. For this reason, ART must be used in combination with one or more partner drugs that ensure complete cure. The ability of malaria parasites to survive ART monotherapy may relate to an innate growth bistability phenomenon whereby a fraction of the drug-exposed population enters into metabolic quiescence (dormancy) as persister forms. Characterization of the events that underlie entry and waking from persistence may lead to lasting breakthroughs in malaria chemotherapy that can prevent recrudescences and protect the future of ART-based combination therapies.

青蒿素及其衍生物 (ART) 是重要的一线抗疟药物，可快速清除寄生虫血症，但在 ART 单药治疗后感染复发频繁。因此，ART 必须与一种或多种伙伴药物联合使用，以确保完全治愈。疟疾寄生虫在 ART 单药治疗中存活的能力可能与先天生长双稳态现象有关，即一部分暴露于药物的种群以持久性形式进入代谢静止（休眠）状态。表征进入和从持久性中苏醒的事件可能会导致疟疾化学疗法的持久突破，从而防止复发并保护基于 ART 的联合疗法的未来。